BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29057423)

  • 1. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
    Kieny A; Kremer V; Scheidecker S; Lipsker D
    Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423
    [No Abstract]   [Full Text] [Related]  

  • 2. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
    Wolfe CM; Green WH; Cognetta AB; Hatfield HK
    Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
    Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
    N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps.
    Ally MS; Tang JY; Lindgren J; Acosta-Raphael M; Rezaee M; Chanana AM; Epstein EH
    JAMA Dermatol; 2015 Oct; 151(10):1132-4. PubMed ID: 26200175
    [No Abstract]   [Full Text] [Related]  

  • 5. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
    Yang X; Dinehart SM
    JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945
    [No Abstract]   [Full Text] [Related]  

  • 6. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
    Chang AL; Atwood SX; Tartar DM; Oro AE
    JAMA Dermatol; 2013 May; 149(5):639-41. PubMed ID: 23677114
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome.
    Ally MS; Wysong A; Tang JY; Aasi S
    Dermatol Surg; 2013 Sep; 39(9):1413-4. PubMed ID: 23682843
    [No Abstract]   [Full Text] [Related]  

  • 8. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Tang JY; Ally MS; Chanana AM; Mackay-Wiggan JM; Aszterbaum M; Lindgren JA; Ulerio G; Rezaee MR; Gildengorin G; Marji J; Clark C; Bickers DR; Epstein EH
    Lancet Oncol; 2016 Dec; 17(12):1720-1731. PubMed ID: 27838224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
    Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
    Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic changes in basal cell carcinoma after treatment with vismodegib.
    Aldabagh B; Yu J; Perkocha LA; Arron S
    Dermatol Surg; 2013 Nov; 39(11):1703-5. PubMed ID: 23879864
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe Rheumatoid Arthritis Developing in Conjunction with Gorlin Syndrome.
    Scott JF; Bordeaux JS
    J Rheumatol; 2016 Jul; 43(7):1447-9. PubMed ID: 27371652
    [No Abstract]   [Full Text] [Related]  

  • 14. Enlarging Multiple Neoplastic Skin Growths.
    Feinstein EG; Zhou M; Setabutr P
    JAMA Ophthalmol; 2016 Mar; 134(3):337-8. PubMed ID: 26767432
    [No Abstract]   [Full Text] [Related]  

  • 15. Vismodegib in basal cell carcinoma.
    Amaria RN; Bowles DW; Lewis KD; Jimeno A
    Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
    Lear JT
    N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909
    [No Abstract]   [Full Text] [Related]  

  • 18. Reversible cutaneous side effects of vismodegib treatment.
    Kwong B; Danial C; Liu A; Chun KA; Chang AL
    Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of trichodysplasia spinulosa: case report of a patient with Gorlin syndrome treated with vismodegib.
    Richey JD; Graham TA; Katona T; Travers JB
    JAMA Dermatol; 2014 Sep; 150(9):1016-8. PubMed ID: 25054782
    [No Abstract]   [Full Text] [Related]  

  • 20. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
    Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.